Hormonal
Low endogenous melatonin production (defined as urinary 6-SMT ≤8 μg/night) is NOT a useful predictor of response to melatonin therapy in insomnia patients.
You do not need to get your melatonin levels tested to decide if melatonin might help your sleep. The study shows that low melatonin levels do not predict whether you will respond to melatonin therapy. Instead, being over 65 is a better indicator of potential benefit.
Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.
Why this rating
Based on the same high-quality RCT, specifically the subgroup analysis of low excretors.
Source
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
Alan Wade et al. · BMC Medicine · 2010
DOI 10.1186/1741-7015-8-51
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →